Definium Therapeutics (DFTX) Return on Capital Employed (2022 - 2026)
Definium Therapeutics' (DFTX) quarterly Return on Capital Employed came in at 56.94% in Q1 2026, down 1285.0% year-on-year from 4.81% in Q1 2025, and up 6.93% on a QoQ basis from 61.19% in Q4 2025.
Definium Therapeutics (DFTX) Return on Capital Employed (2022 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 5 years of Return on Capital Employed data on file, last reported at 56.94% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 1285.0% year-over-year to 56.94% in Q1 2026; TTM through Mar 2026 was 56.94%, a 1285.0% decrease from a year earlier, with the FY2025 full-year figure at 54.63%, up 492.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 56.94%, up from 61.19% in the prior quarter.
- Over the last five years, Return on Capital Employed for DFTX reached as high as 35.93% in Q3 2024 and fell as low as 93.12% in Q4 2023.
- Historically, Return on Capital Employed has averaged 58.25% across 5 years, with a median of 56.11% in 2025.
- Across the five-year window, Return on Capital Employed tumbled 5102 bps in 2023 and surged 5493 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 42.1% in 2022, then tumbled by 121 bps to 93.12% in 2023, then jumped by 59 bps to 38.19% in 2024, then tumbled by 60 bps to 61.19% in 2025, then grew by 7 bps to 56.94% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 56.94% in Q1 2026, 61.19% in Q4 2025, and 81.47% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Definium Therapeutics | 4.47 Bn | 4.47 Bn | - | -56.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.94% |
| Dec 31, 2025 | -61.19% |
| Sep 30, 2025 | -81.47% |
| Jun 30, 2025 | -56.11% |
| Mar 31, 2025 | -44.09% |
| Dec 31, 2024 | -38.19% |
| Sep 30, 2024 | -35.93% |
| Jun 30, 2024 | -39.34% |
| Mar 31, 2024 | -70.65% |
| Dec 31, 2023 | -93.12% |
| Sep 30, 2023 | -77.32% |
| Jun 30, 2023 | -71.19% |
| Mar 31, 2023 | -49.54% |
| Dec 31, 2022 | -42.10% |
| Sep 30, 2022 | -53.20% |
| Jun 30, 2022 | -52.46% |
| Mar 31, 2022 | -67.45% |